Allogene Therapeutics Announces Participation in Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard…
SCHEDULE 13G/A: SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
SCHEDULE 13G/A: SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
- 1
- 2
- 3
- 4
- …
- 16
- Go to the next page